CareDx (CDNA) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.37
- Estimate
- $0.23
- Surprise
- +59.5%
- Revenue (period 2026-06-30)
- $131.9M
- Score at report (before → after)
- 6.0 → 5.9/10
Revenue source: xbrl.
How the report landed
CareDx (CDNA) beat the $0.23 estimate with adjusted EPS of $0.37 — a large 59.5% upside surprise. TrendMatrix's engine moved from Buy (Wait) (6.0/10) to Hold at 5.9/10 after the report — the engine's score fell despite the beat.
Where TrendMatrix's rating stands now
TrendMatrix currently rates CDNA Hold at 6.3/10.
3 of the last 4 quarters beat the estimate; this quarter's +59.5% surprise compares with a +87.1% four-quarter average. Next scheduled report: 2027-02-24.
What supports the rating
- Strong earnings beat streak (3/4)
- High-quality business
What argues against it
- Concentration risk — Product: AlloSure/AlloMap/HeartCare transplant tests
- Negative momentum
- Value-trap signals (2/5): Margin compression (op margin 1.6%), Material insider selling (11 sells, 0.13% of cap)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $73.72
- Price target
- $82.15
- Stop
- $68.56
- Upside to target
- +11.4%
- Reward-to-risk
- 0.8:1
Forward estimates sit below the trailing run-rate (49.8× forward vs 32.9× trailing) — consensus expects earnings to decline from here.
Model outputs from TrendMatrix’s engine as of 2026-11-17 — shown for context, not personalized investment advice.
CDNA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Diagnostics & Research
- Market cap
- $4.09B
- P/E (fwd)
- 49.8
- P/E (ttm)
- 32.9
- 52-week range
- $15.15–$90.87
- Off 52-week high
- 18.9%
- RSI (14)
- 53
- Volume vs avg
- 0.77×
- Score today
- 6.3/10